CompletedPhase 1NCT03815396

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Inhibrx Biosciences, Inc
Principal Investigator: Vasily Andrianov, MD
Inhibrx Biosciences, Inc
Intervention: INBRX-101/rhAAT-Fc(drug)
Enrollment: 31 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2019 – 2022

Study locations (10)

UC Davis School of Medicine, Sacramento, California, United States
University of Florida College of Medicine, Gainesville, Florida, United States
University of Miami, Miami, Florida, United States
Indiana University, Indianapolis, Indiana, United States
Hannibal Clinic, Hannibal, Missouri, United States
The New Zealand Respiratory and Sleep Institute, Auckland, New Zealand
Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand
Waikato Respiratory and Gastro Research Unit, Hamilton, New Zealand
University of Cambridge, Cambridge, East of England, United Kingdom
University Hospital Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03815396 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials